GO:0031762 follicle-stimulating hormone receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0031762 (follicle-stimulating hormone receptor binding) is a molecular function describing the binding of follicle-stimulating hormone (FSH) to its receptor (FSHR).
• FSH is a heterodimeric glycoprotein hormone whose oligosaccharide structures influence receptor binding and bioactivity.
• FSHR is a G-protein-coupled receptor; hormone binding triggers allosteric activation and downstream cAMP signaling.
• FSH-FSHR binding is not restricted to gonads; it also affects pancreatic islet insulin secretion, adipose thermogenesis, bone resorption, and cancer biology.
• The interaction can be modulated by allosteric small molecules and by glycosylation of the hormone, making it a target for pharmacological intervention.
• CRISPR-based knockout, knock-in, and point-mutation models are essential to dissect the causal roles of FSH-FSHR binding in physiology and disease.
Description
GO:0031762, follicle-stimulating hormone receptor binding, is a molecular function term that captures the physical interaction between follicle-stimulating hormone (FSH) and its cognate receptor (FSHR). FSH is a pituitary glycoprotein hormone that belongs to the gonadotropin family, and its binding to FSHR is the first step in a signaling cascade that regulates gonadal development and function. The term is defined as binding to a follicle-stimulating hormone receptor, and it is a critical node for understanding how endocrine signals are translated into cellular responses. Researchers study this term because perturbations in FSH-FSHR binding are linked to reproductive disorders, metabolic diseases, and cancer. The interaction is also a model system for understanding glycoprotein hormone-receptor recognition and allosteric regulation.
follicle-stimulating hormone receptor binding At A Glance
| GO ID | GO:0031762 |
|---|---|
| GO term | follicle-stimulating hormone receptor binding |
| Ontology | molecular_function |
| Synonym | follicle stimulating hormone receptor binding; follicle stimulating hormone receptor ligand; FSH receptor binding |
| Major function | Binding of FSH to its receptor FSHR, initiating receptor activation and downstream signaling |
| Major ligands | Follicle-stimulating hormone (FSH), a heterodimeric glycoprotein hormone |
| Major receptor | Follicle-stimulating hormone receptor (FSHR), a G-protein-coupled receptor |
| Regulation | Modulated by hormone glycosylation and allosteric small molecules |
| Disease relevance | Reproductive disorders, metabolic diseases, bone loss, and cancer |
What Is GO:0031762?
According to the Gene Ontology, GO:0031762 (follicle-stimulating hormone receptor binding) is a molecular function defined as binding to a follicle-stimulating hormone receptor. In other words, it describes the selective, non-covalent association of FSH with FSHR, an event that initiates receptor activation and downstream signaling. This function is distinct from receptor activation itself, although binding is a prerequisite for the conformational changes that lead to G-protein coupling and second messenger production.
Why Is follicle-stimulating hormone receptor binding Important in Cell Biology?
Understanding GO:0031762 is fundamental because FSH-FSHR binding is the molecular switch that controls gonadal function and also has extra-gonadal roles in metabolism, bone remodeling, and tumor progression. The binding event is highly specific and is influenced by the glycosylation state of FSH, which can alter receptor affinity and signal duration. Moreover, FSHR can be activated by allosteric modulators, making the binding interface a potential drug target. Thus, this GO term bridges basic endocrinology with translational research in reproductive medicine, oncology, and metabolic disease.
• FSH-FSHR binding is essential for folliculogenesis and spermatogenesis.
• It regulates glucose-stimulated insulin secretion in pancreatic islets.
• Blocking FSH binding reduces body fat and induces thermogenic adipose tissue.
• FSH exacerbates bone loss by promoting osteoclast energy metabolism.
• FSH and its receptor are implicated in cancer cell proliferation and survival.
• The binding interaction is a target for allosteric modulators of FSHR.
• Glycosylation of FSH modulates receptor binding and bioactivity.
• Crystal structures of FSH-FSHR complexes have clarified the binding mechanism.
• FSHR mutations can cause reproductive disorders, highlighting the importance of binding.
• CRISPR models enable causal testing of FSH-FSHR binding in vivo.
What Happens During follicle-stimulating hormone receptor binding?
Recognition and initial contact
In simple terms: FSH finds and docks onto its receptor on the cell surface.
The binding process begins with the recognition of FSHR by FSH. FSH is a heterodimer composed of a common alpha subunit and a hormone-specific beta subunit, and its glycans contribute to receptor recognition. The extracellular domain of FSHR contains leucine-rich repeats that form the primary binding site for FSH. This initial contact is highly specific, ensuring that FSH binds to FSHR and not to other glycoprotein hormone receptors.
Conformational change and receptor activation
In simple terms: Once bound, the receptor changes shape and turns on signaling.
Upon FSH binding, FSHR undergoes a conformational change that leads to activation of the associated Gs protein and production of cAMP. This activation is an allosteric process, and the binding energy is transduced through the receptor's transmembrane domains. The crystal structure of the FSH-FSHR complex has provided insights into how hormone binding triggers receptor activation.
Downstream signaling and cellular responses
In simple terms: The activated receptor sends signals that change cell behavior.
Activated FSHR stimulates multiple signaling pathways, including cAMP/PKA, which regulates gene expression and steroidogenesis in gonadal cells. In pancreatic islets, FSH-FSHR binding orchestrates glucose-stimulated insulin secretion. In osteoclasts, FSH binding promotes energy metabolism through the CREB-MDH2-NAD+ axis, exacerbating bone loss. These diverse responses underscore the pleiotropic roles of this binding event.
Modulation by glycosylation and allosteric ligands
In simple terms: The strength and duration of binding can be tuned by sugar modifications and small molecules.
The glycosylation state of FSH affects its binding affinity and intrinsic bioactivity at FSHR. Additionally, small molecule allosteric modulators can enhance or inhibit FSH binding and receptor activation. These regulatory layers provide opportunities for pharmacological intervention.
Key Genes Involved in GO:0031762 follicle-stimulating hormone receptor binding
The following genes and proteins are central to follicle-stimulating hormone receptor binding and its downstream effects.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FSHR | Receptor for FSH; mediates binding and activation | Mutations cause reproductive disorders; target for allosteric drugs |
| FSHB | Beta subunit of FSH; confers receptor binding specificity | Glycosylation affects binding affinity |
| CGA | Common alpha subunit of glycoprotein hormones | Required for FSH assembly and secretion |
| GNAS | G protein alpha subunit; couples FSHR to cAMP | Mediates downstream signaling after binding |
| CREB1 | Transcription factor activated by FSH signaling | Regulates gene expression in osteoclasts and gonads |
| MDH2 | Malate dehydrogenase 2; involved in osteoclast energy metabolism | FSH promotes bone loss via CREB-MDH2-NAD+ axis |
| INS | Insulin; regulated by FSH in pancreatic islets | FSH orchestrates glucose-stimulated insulin secretion |
| UCP1 | Uncoupling protein 1; thermogenic marker | Blocking FSH induces thermogenic adipose tissue |
| PRKACA | Catalytic subunit of PKA; downstream of cAMP | Mediates FSH-induced signaling |
| AKT1 | Kinase involved in cell survival and proliferation | FSH signaling in cancer |
| MAPK1 | MAP kinase; downstream of FSHR | Regulates proliferation in FSH-responsive cancers |
| ESR1 | Estrogen receptor; crosstalk with FSH signaling | Modulates gonadal and metabolic effects |
| AR | Androgen receptor; involved in spermatogenesis | FSH supports androgen production |
| LHCGR | Luteinizing hormone receptor; related glycoprotein hormone receptor | Comparative studies of binding specificity |
| TSHR | Thyroid-stimulating hormone receptor; related receptor | Structural insights into glycoprotein hormone binding |
| BMP15 | Oocyte-derived growth factor; interacts with FSH signaling | Regulates folliculogenesis |
| GDF9 | Oocyte-derived growth factor; modulates granulosa cell function | Crosstalk with FSH signaling |
How Is follicle-stimulating hormone receptor binding Regulated?
The binding of FSH to FSHR is regulated at multiple levels. The glycosylation of FSH modulates its receptor binding affinity and bioactivity. Allosteric small molecules can bind to FSHR and alter its response to FSH. Additionally, receptor expression levels and post-translational modifications of FSHR can influence binding capacity. Downstream signaling feedback, such as cAMP-mediated desensitization, also regulates the duration of the binding response.
follicle-stimulating hormone receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FSHR | Ovarian dysgenesis, premature ovarian failure | FSHR knockout mouse; patient-derived iPSCs |
| FSHB | Hypogonadotropic hypogonadism | FSHB knockout mouse; knock-in of glycosylation mutants |
| CREB1 | Bone loss via osteoclast activation | Osteoclast-specific Creb1 knockout |
| MDH2 | Osteoclast energy metabolism in osteoporosis | Mdh2 knockout or point-mutation models |
| INS | Diabetes and insulin secretion defects | Pancreatic islet-specific Fshr knockout |
Reproductive disorders
Mutations in FSHR that impair FSH binding can cause ovarian dysgenesis, premature ovarian failure, and spermatogenic failure. Understanding the binding interface is critical for diagnosing and treating these conditions.
Metabolic diseases
FSH-FSHR binding influences glucose-stimulated insulin secretion in pancreatic islets, linking it to diabetes and metabolic syndrome. Blocking FSH binding reduces body fat and induces thermogenic adipose tissue, suggesting a role in obesity.
Bone loss
FSH binding to FSHR on osteoclasts promotes bone resorption through the CREB-MDH2-NAD+ axis, contributing to osteoporosis. Inhibiting this interaction may be a therapeutic strategy for bone loss.
Cancer
FSH and its receptor are expressed in various cancers, where FSH-FSHR binding can promote proliferation and survival. Targeting this interaction is being explored as an anti-cancer strategy.
From follicle-stimulating hormone receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does FSHR mediate FSH-dependent insulin secretion? | Pancreatic beta-cell-specific Fshr knockout |
| Does FSH glycosylation affect receptor binding? | Knock-in of FSHB glycosylation site mutants |
| Can allosteric modulators alter FSH binding? | Point mutations in FSHR allosteric pocket |
| Does blocking FSH reduce body fat? | FSH-neutralizing antibody in mice; Fshr knockout |
| Does FSH promote bone loss via osteoclasts? | Osteoclast-specific Fshr knockout or Mdh2 knockout |
| Is FSHR involved in cancer growth? | Xenograft models with FSHR overexpression or knockout |
How to Study the follicle-stimulating hormone receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding | Binding affinity and kinetics | Characterizing FSH-FSHR interaction |
| Surface plasmon resonance | Real-time binding kinetics | Allosteric modulator screening |
| cAMP assay | Receptor activation | Functional characterization of FSHR mutants |
| Crystal structure | Molecular details of binding interface | Structure-guided drug design |
| CRISPR knockout screen | Genes affecting FSH signaling | Discovery of novel regulators |
| RNA-seq | Transcriptional changes upon FSH binding | Identifying downstream targets |
| Proteomics | Protein interactions and modifications | Mapping FSHR signaling complexes |
| Imaging | Receptor localization and trafficking | Visualizing FSH-FSHR binding in cells |
Binding assays
Radioligand binding assays using iodinated FSH are classic methods to measure FSH-FSHR binding affinity and kinetics. Surface plasmon resonance (SPR) can provide real-time binding kinetics.
Structural biology
Crystal structures of the FSH-FSHR complex have revealed the molecular details of the binding interface. Cryo-EM can be used for larger complexes.
Cell-based signaling assays
cAMP accumulation assays and luciferase reporter assays are used to measure FSHR activation following FSH binding. These assays are amenable to high-throughput screening for allosteric modulators.
CRISPR screening
Genome-wide CRISPR knockout screens can identify genes that modulate FSH-FSHR binding and downstream signaling. These screens are powerful for discovering novel regulators.
How CRISPR Can Be Used to Study GO:0031762 follicle-stimulating hormone receptor binding
Knockout
CRISPR knockout of FSHR or FSHB can abolish FSH-FSHR binding, providing a clean background to study downstream effects. For example, Fshr knockout mice exhibit impaired folliculogenesis and metabolic phenotypes.
Point Mutation
Point mutations in the FSHR binding pocket can be introduced to dissect the contribution of specific residues to FSH binding. Such models are valuable for understanding receptor activation mechanisms.
Knock-in
Knock-in of tagged FSHR or mutant FSHB allows tracking of receptor localization and glycosylation effects on binding. This approach can also be used to create disease-associated mutations.
Overexpression
Overexpression of FSHR in cell lines or transgenic animals can enhance FSH binding and amplify downstream signaling, useful for studying cancer and metabolic effects.
How EDITGENE Supports follicle-stimulating hormone receptor binding Research
Researchers studying follicle-stimulating hormone receptor binding-related genes often need to determine whether a candidate gene is causally involved in FSH-FSHR interaction and its downstream phenotypes. EDITGENE provides a comprehensive suite of CRISPR services to enable such investigations, from knockout to knock-in and library screening.
Contact EDITGENE today to design your custom CRISPR model for follicle-stimulating hormone receptor binding research.
Frequently Asked Questions About follicle-stimulating hormone receptor binding
What is follicle-stimulating hormone receptor binding?
It is the molecular function defined by GO:0031762, describing the binding of FSH to its receptor FSHR, which initiates signaling.
What genes are involved in follicle-stimulating hormone receptor binding?
Key genes include FSHR, FSHB, CGA, and downstream signaling genes like GNAS and CREB1.
What is the role of FSHR in FSH binding?
FSHR is the receptor that specifically binds FSH, leading to receptor activation and downstream signaling.
How does FSH binding affect insulin secretion?
FSH-FSHR binding in pancreatic islets orchestrates glucose-stimulated insulin secretion.
Can blocking FSH binding reduce body fat?
Yes, blocking FSH induces thermogenic adipose tissue and reduces body fat in mice.
What diseases are associated with FSH receptor binding?
Reproductive disorders, osteoporosis, metabolic diseases, and cancer.
How is FSH-FSHR binding regulated?
It is regulated by FSH glycosylation and allosteric modulators of FSHR.
What experimental models study FSH receptor binding?
Knockout mice, point-mutation cell lines, and knock-in models are commonly used.
What is the structure of the FSH-FSHR complex?
Crystal structures have revealed the binding interface and activation mechanism.
How can CRISPR help study FSH receptor binding?
CRISPR knockout, knock-in, and point mutations enable causal testing of genes involved in FSH-FSHR binding.
Conclusion
GO:0031762 follicle-stimulating hormone receptor binding is a central molecular function that mediates the diverse actions of FSH in reproduction, metabolism, bone, and cancer. Understanding its mechanism, regulation, and disease relevance is essential for developing targeted therapies. CRISPR-based models and EDITGENE services provide powerful tools to dissect this interaction and translate findings into clinical applications.
References
- 1. Cheng Y et al.. 2023. Follicle-stimulating hormone orchestrates glucose-stimulated insulin secretion of pancreatic islets.. Nat Commun 14(1):6991 PMID: 37914684
- 2. Bousfield GR et al.. 2019. Follicle-Stimulating Hormone Glycobiology.. Endocrinology 160(6):1515-1535 PMID: 31127275
- 3. Gudermann T et al.. 2005. Hormone binding to the follicle-stimulating hormone receptor--crystal clear!. Exp Clin Endocrinol Diabetes 113(5):245-7 PMID: 15926107
- 4. Nataraja S et al.. 2018. Allosteric Regulation of the Follicle-Stimulating Hormone Receptor.. Endocrinology 159(7):2704-2716 PMID: 29800292
- 5. De Pascali F et al.. 2018. Follicle-Stimulating Hormone Receptor: Advances and Remaining Challenges.. Int Rev Cell Mol Biol 338:1-58 PMID: 29699689
- 6. Li Y et al.. 2026. Follicle-stimulating hormone and cancer.. Cell Signal 147:112738 PMID: 42442675
- 7. Liu P et al.. 2017. Blocking FSH induces thermogenic adipose tissue and reduces body fat.. Nature 546(7656):107-112 PMID: 28538730
- 8. Chen J et al.. 2025. FSH exacerbates bone loss by promoting osteoclast energy metabolism through the CREB-MDH2-NAD(+) axis.. Metabolism 165:156147 PMID: 39880362
